Showing 3371-3380 of 6035 results for "".
- Feliqs Secures $9 Million Series A to Advance FLQ-101 Clinical Trial for Retinopathy of Prematurityhttps://modernod.com/news/feliqs-secures-9-million-series-a-to-advance-flq-101-clinical-trial-for-retinopathy-of-prematurity/2482869/Feliqs Corp. announced the successful completion of a $9 million Series A financing round to advance the company's lead investigational therapy, FLQ-101, into clinical development. Designed as a once-daily oral or intravenous formulation, FLQ-101 aims
- ForSight Robotics Secures $125 Million in Series B Fundinghttps://modernod.com/news/forsight-robotics-secures-125-million-in-series-b-funding-addressing-global-surgeon-shortage-and-demand-for-ophthalmic-surgery/2482862/ForSight Robotics announced it has completed a $125M Series B round, led by Eclipse. The investment accelerates the next growth phase for the ORYOM Platform, the world’s first robotic surgery platform for cataract and other eye diseases designed to enhance surgical precision, incr
- Alcon Introduces Clareon PanOptix Pro in Canadahttps://modernod.com/news/alcon-introduces-clareon-panoptix-pro-in-canada/2482857/Alcon announced the approval of Clareon PanOptix Pro IOL in Canada. According to Alcon, PanOptix Pro leverages the company's proprietary 'ENLIGHTEN NXT' optical technology, which delivers the lowest light scatter and highest reported light utilization of
- Sightview Appoints Tycene Fritcher as CEOhttps://modernod.com/news/sightview-appoints-tycene-fritcher-as-ceo/2482850/Ophthalmic Electronic health record (EHR) provider Sightview announced that Tycene Fritcher has been appointed Chief Executive Officer. Ms. Fritcher brings more than two decades of leadership experience in healthcare IT, including tenures at Nextech, Avizia, and Am
- NIH Study: Experimental Drug May Help Treat Condition May Help Treat Diabetic Retinopathyhttps://modernod.com/news/nih-study-experimental-drug-may-help-treat-condition-may-help-treat-diabetic-retinopathy/2482805/A new National Institutes of Health (NIH)-funded study led by scientists at the Wilmer Eye Institute, Johns Hopkins Medicine researchers determined that low blood sugar, or hypoglycemia, may promote a breakdown of the blood-retinal barrier, an important boundary that regulates the flow of nu
- Bausch + Lomb Launches Zenlens CHROMA HOA in the UShttps://modernod.com/news/bausch-lomb-launches-zenlens-chroma-hoa-in-the-us/2482802/Bausch + Lomb announced the US launch of Zenlens CHROMA HOA scleral contact lenses. Designed to correct advanced higher-order aberrations (HOA), this custom, wavefront-guided scleral lens technology delivers enhanced vision and improves clarity by reducing symptoms such as halos an
- Aldeyra Plans to Resubmit NDA for DED Candidate Reproxalap After Dry Eye Chamber Trial Resultshttps://modernod.com/news/aldeyra-plans-to-resubmit-nda-for-ded-candidate-reproxilap-after-dry-eye-chamber-trial-results/2482788/Aldeyra Therapeutics announced it has achieved the primary endpoint in a phase 3 randomized, double-masked, vehicle-controlled dry eye chamber trial of its investigational drug candidate reproxalap.
- FDA Once Again Rejects Aldeyra's NDA of Reproxalap for Dry Eye Diseasehttps://modernod.com/news/fda-once-again-rejects-aldeyras-nda-of-reproxalap-for-dry-eye-disease/2482727/The FDA issued a complete response letter declining to approve Aldeyra Therapeutics' resubmitted new drug application (NDA) of reproxalap, an investigational drug candidate for the treatment of dry eye disease. Although no manufacturing or safety issues with repr
- Alcon Launches Clareon PanOptix Pro Trifocal IOLhttps://modernod.com/news/alcon-launches-clareon-panoptix-pro-trifocal-iol/2482725/Alcon has introduced the Clareon PanOptix Pro IOL in the US. According to Alcon, PanOptix Pro leverages proprietary 'ENLIGHTEN NXT' Optical technology, which is designed
- Rayner Expands IOL Manufacturing Capacity to Meet Growing Demandhttps://modernod.com/news/rayner-expands-iol-manufacturing-capacity-to-meet-growing-demand/2482723/Rayner has completed a major expansion of its production facility in Worthing, UK, doubling its annual IOL manufacturing capacity to 4 million units, the company announced. Since opening its manufacturing pl